Abstract
Phase I/II studies of gemtuzumab ozogamicin (GO) in pediatric refractory/relapsed acute myeloid leukemia (AML) have been reported. We present the cases of two children with relapsed AML who were treated with GO plus cytarabine, leading to a decrease of minimal residual disease down to levels not previously obtained. The toxicity profile of this treatment was relatively mild, except for severe but manageable myelosuppression.
MeSH terms
-
Adolescent
-
Aminoglycosides / administration & dosage
-
Aminoglycosides / adverse effects
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Female
-
Gemtuzumab
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / prevention & control
-
Male
-
Neoplasm Recurrence, Local / prevention & control*
Substances
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Cytarabine
-
Gemtuzumab